Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab.

Introduction: Approximately 3%-10% of asthma patients will remain uncontrolled despite maximum, optimal conventional therapy. Treatment of severe refractory asthma often involves the use of targeted biological therapy. Randomised controlled trials have shown improvements in clinical parameters with these treatments but real-world data is lacking.